$5.16B in CY2024 Part D spend199K claims · 48K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Ustekinumab used for?
Ustekinumab-aekn is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or s....
Is there a generic for Ustekinumab?
No. Ustekinumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Ustekinumab?
Across 329 Part D plans, Ustekinumab averages $20844.79/unit (NADAC). Lowest available: $2898.19/unit. Highest in distribution: $29841.65/unit.
Is Ustekinumab on the FDA shortage list?
No. Ustekinumab is not currently on the FDA Drug Shortage Database.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.